Skip to main content
SHANGHAI OPM BIOSCIENCES CO., LTD. logo

SHANGHAI OPM BIOSCIENCES CO., LTD. — Investor Relations & Filings

Ticker · 688293 ISIN · CNE100005PF1 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 624 across all filing types
Latest filing 2026-05-15 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688293

About SHANGHAI OPM BIOSCIENCES CO., LTD.

https://www.opmbiosciences.com/

Shanghai OPM Biosciences Co., Ltd. specializes in the development of high-end cell culture media and the provision of comprehensive CDMO services. The company offers a diverse portfolio of serum-free media products tailored for various cell lines, including CHO, HEK293, and insect cells, supporting the production of recombinant proteins, antibodies, and vaccines. OPM provides end-to-end bioprocess development and manufacturing services, ranging from cell line development to pilot-scale production. By integrating media optimization with process engineering, the company aims to enhance yields and reduce costs for biopharmaceutical clients. Its technical platform focuses on high-performance formulations designed to meet rigorous regulatory standards and facilitate the transition from laboratory research to commercial-scale manufacturing.

Recent filings

Filing Released Lang Actions
奥浦迈：2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document is an official announcement of the annual shareholders meeting resolutions and detailed voting results on multiple proposals (annual report, board work report, remuneration, profit distribution etc.). It does not contain the actual financial report itself but reports the results of shareholder votes at the AGM. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-15 Chinese
上海市方达律师事务所关于上海奥浦迈生物科技股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 12% confidence The document is a legal opinion letter from the company’s law firm regarding the convening, procedures, voting eligibility, and results of the 2025 Annual General Meeting. It is neither the AGM presentation itself nor the formal minutes or voting results announcement; rather, it is a legal counsel certification. It does not contain financial statements or constitute a proxy solicitation. Therefore, it does not fit any specific category and falls under the fallback Regulatory Filings (RNS).
2026-05-15 Chinese
奥浦迈：关于持股5%以上的股东减持股份计划公告
Major Shareholding Notification Classification · 88% confidence The document is an official Shanghai Stock Exchange announcement titled “关于部分持股5%以上股东减持股份计划公告,” detailing planned share disposals by three shareholders holding over 5%. It outlines their current holdings, planned reduction amounts and periods, disposal methods, and compliance with listing rules. This is a pre-disclosure of a major shareholding change rather than a corporate buyback or a report of quarterly/annual results. Therefore, it falls under “Major Shareholding Notification” (MRQ).
2026-05-11 Chinese
奥浦迈：关于召开2026年第一季度业绩说明会的公告
Regulatory Filings Classification · 80% confidence The document is an announcement of an upcoming investor performance briefing for the 2026 Q1 results (a Q&A session/network interactive meeting). It does not contain actual financial data or the text of the presentation/transcript; it merely notifies investors of the meeting logistics and references the previously published Q1 report. This does not qualify as an Earnings Release (ER), Interim Report (IR), Investor Presentation (IP), or Transcript (CT). It is a generic regulatory announcement, best classified under the fallback category Regulatory Filings (RNS).
2026-05-11 Chinese
国泰海通证券关于上海奥浦迈生物科技股份有限公司2025年度持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2025年度持续督导工作现场检查报告" which translates to "2025 Annual Continuous Supervision On-site Inspection Report" by the sponsor (underwriter) for a listed company. It details the sponsor's on-site inspection activities, including governance, internal controls, information disclosure, independence, related party transactions, use of raised funds, and operational status. The document is a detailed report of the sponsor's supervisory work during the year 2025, including findings and conclusions. It is not an annual report (10-K), nor an audit report (AR), nor a regulatory filing (RNS) or announcement. It is a standalone report focused on the sponsor's continuous supervision and inspection work, which aligns with the category of Audit Report / Information (AR) as it involves regulatory compliance, internal controls, and inspection results but is not a full annual report. The document length is 2883 characters, which is sufficient for a detailed report but not a brief announcement. Therefore, the best fit is Audit Report / Information (AR). FY 2025
2026-05-07 Chinese
国泰海通证券股份有限公司关于上海奥浦迈生物科技股份有限公司首次公开发行股票并上市之保荐总结报告书
Regulatory Filings Classification · 95% confidence The document is titled as a "保荐总结报告书" which translates to "Sponsorship Summary Report" related to the initial public offering (IPO) and listing of Shanghai Aopumai Biotechnology Co., Ltd. It details the sponsorship institution's responsibilities, the IPO process, continuous supervision, and compliance with regulatory requirements. It includes information about the underwriting, due diligence, ongoing supervision, and evaluation of the issuer's compliance and fund usage. The document is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement or certification. It is a detailed summary report issued by the sponsor after the IPO and listing process, which fits the category of a Regulatory Filing (RNS) as it is a regulatory compliance document related to the IPO process and supervision, but does not fit other more specific categories such as Capital/Financing Update or M&A Activity. The document length is 3565 characters, which is relatively short but contains substantive content about the sponsorship and supervision activities. Therefore, the best classification is Regulatory Filings (RNS).
2026-05-07 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.